Prevenar13 Post Market Surveillance

Post Marketing Surveillance To Observe Safety Of Prevenar 13

It is an observational multi-center study to assess the safety profile of Prevenar13 used among Korean children in the routine clinical setting following a licensure and introduction of the vaccine. This study is designed to fulfill regulatory requirement for any new drug authorized by KFDA.

non-randomization, non-probability sampling

Inclusion Criteria:

• Infants and children aged 6 weeks to 5 years, whose legally authorized representatives of patients agree to provide written informed consent form (data privacy statement).

Exclusion Criteria:

• Infants and children who are not indicated and/or contraindicated for the Prevenar13 usage will not be included.